Ophthalmology News

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Paulo-Eduardo Stanga, MD, speaks in favor of treating vitreous floaters and opacities.

NEW YORK — In this Healio Video Perspective from OSN New York, Mitchell A. Jackson, MD, of Jacksoneye in Lake Villa, Illinois, discusses the benefits of corneal tissue addition keratoplasty for patients with keratoconus.

Why not just invest in one stock and let it ride? That works well if you bet the farm on Apple in 2010 and watched your fortune explode 30 time during the last 14 years.

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Diana Do, MD, discusses the PHOTON extension study, which examined the effect of Eylea HD in patients with diabetic macular edema.

NEW YORK — In this Healio Video Perspective from OSN New York, Sanjay Nayak, MBBS, PhD, of Ocular Therapeutix discusses Axpaxli for the treatment of retinal vascular diseases.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company’s oral therapy for the treatment of Stargardt’s disease and age-related macular degeneration.

BARCELONA, Spain – In this Healio Video Perspective from the Euretina congress, David Wong, MD, shares his thoughts on the advantages of new drugs for retinal conditions including age-related macular degeneration.

NEW YORK — In this Healio Video Perspective from OSN New York Retina, Lejla Vajzovic, MD, FASRS, of Duke Eye Center in Durham, North Carolina, discusses the adoption of therapies for the treatment of geographic atrophy.

CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Xiao-Yu Song, MD, PhD, of Johnson & Johnson Vision, gives an overview of company innovations for improving vision outcomes in refractive and cataract surgery.

CHICAGO — In this Healio Video Perspective from Retina Subspecialty Day at the AAO meeting, Carl D. Regillo, MD, FACS, of Wills Eye Hospital, shares study results from the phase 2 DAVIO 2 trial.